September 24, 2026 · Phase 2 readout
NVSEF Phase 2 readout: a neutral outcome, +3.0%
On September 24, 2026, YTB323 — NOVARTIS AG (Systemic Lupus Erythematosus) reached its Phase 2 readout. The result was a neutral outcome, and the stock moved +3.0% in the window around the event. It had already run -15.5% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.
The move
$138.38
1d before
$142.51
Event day
$140.96
1d after
$144.94
5d after
Our prediction vs. the result
CatalystAlert called this one neutral (+0.0% expected); the stock actually moved +3.0%. Model confidence at the time: 95%.
See the full scored track recordPre-catalyst setup
-15.5%
30-day run-up
8829%
30-day volatility
0.0×
volume spike